NGM Bio Secures $122 Million in Funding After Going Private

1. Funding Amount: NGM Bio has secured $122 million in funding from The Column Group (TCG) after going private earlier this year.
2. New Focus: The company has refined its pipeline to focus on orphan diseases, marking a significant shift in its strategy.
3. Post-Delisting: NGM Bio delisted from the public market earlier this year as part of the take-private deal with TCG.
4. New Look: The company has debuted a new, fit, and focused look following its transition to a private entity.